Co-Authors
This is a "connection" page, showing publications co-authored by Philip Charles Hoffman and Mark K. Ferguson.
Connection Strength
0.352
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.052
-
Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000 Jan; 69(1):245-9; discussion 249-50.
Score: 0.046
-
Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998 Jun; 9(6):647-51.
Score: 0.042
-
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1995 Mar; 2(2):101-6.
Score: 0.033
-
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
Score: 0.026
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.024
-
Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
Score: 0.024
-
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
Score: 0.020
-
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
Score: 0.019
-
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol. 1998 Jun; 16(6):2157-63.
Score: 0.010
-
Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
Score: 0.009
-
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
Score: 0.008
-
Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
Score: 0.008
-
The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
Score: 0.007
-
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
Score: 0.006
-
Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer. Cancer. 1989 Oct 01; 64(7):1404-8.
Score: 0.006
-
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
Score: 0.006
-
Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1987 Nov; 44(5):462-6.
Score: 0.005